Close Menu

BioMérieux EMAG

Nov 10, 2016

BioMérieux has launched eMAG, a molecular biology platform for the extraction of nucleic acids. The platform uses the company's BOOM technology, featuring automation from the primary sample tube, greater traceability, and higher throughput. The system can extract 48 samples in 90 minutes directly from a primary sample, and may be used with a broad variety of biological samples, including whole blood, plasma, serum, stool, respiratory samples, and cerebrospinal fluid.

More Like This

May 28, 2020

Analytik Jena Biometra TRobot II and qTOWER³ Auto Thermal Cyclers

Jena, Germany-based life science firm Analytik Jena has introduced two new thermal cyclers. The Biometra TRobot II is a small footprint PCR module that can be used to save space in a robotic setup, while the qTOWER³ Auto is a qPCR thermal cycler useful for fully automated qPCR applications.

May 21, 2020

Indica Labs, Octo: COVID Digital Pathology Repository

Indica Labs and Octo launched the COVID Digital Pathology Repository, an online collection of high-resolution microscopic COVID-related human tissues hosted at the US National Institutes of Health. The repository enables international collaboration by providing a centralized, cloud-based repository for sharing and annotating digital whle-slide images of lung, liver, kidney, and heart tissues from patients who were infected with the SARS-CoV-2 coronavirus, as well as SARS and MERS. The images, annotations, and metadata will be used as a reference dataset for education, research, and future clinical trials. The repository is underpinned by Indica's Halo Link software, an image management platform. For the repository, Halo Link will be deployed in a web portal developed by Octo and Axle Informatics.

May 19, 2020

Aalto Bio Reagents Recombinant SARS-CoV-2 Spike Proteins

Dublin-based Aalto Bio Reagents has released a range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers globally. The S protein is the main antigenic component that is responsible for inducing host immune responses and neutralizing antibodies, making it the principal focus of therapeutic and vaccine design for COVID-19. When used solely or in combination with Aalto's new insect-derived nucleocapsid protein (N), the company's S1-S2 chimeric glycoprotein has demonstrated excellent reactivity in ELISA for the detection of IgA, IgG and IgM antibodies against SARS-CoV-2, the company said.

May 18, 2020

Beckman Coulter DxH 690T Hematology Analyzer

Beckman Coulter announced the launch of its DxH 690T table-top hematology analyzer in the US. The instrument provides the benefits of the company's large-volume DxH 900 hematology analyzer for a mid-volume setting. The Brea, California-based company said the instrument streamlines throughput, minimizes reflex testing, and reduces manual interventions. Beckman Coulter's Early Sepsis Indicator, a biomarker cleared by the US Food and Drug Administration that can help clinicians detect patients with sepsis or at high risk for developing sepsis, is available on the new analyzer. 

May 11, 2020

LGC SARS-CoV-2 Verification Panel and Reference Materials; Charité ValuPanel Assay Reagents

LGC Seracare has launched new versions of its AccuPlex Verification Panel and Reference Material Kit for SARS-CoV-2 testing. The previous versions contained negative control material targeting the human RNase P gene and positive control material for the viral ORF1a, RdRp, E, and N gene consensus sequences targeted in the US Centers for Disease Control and Prevention and World Health Organization assays. They have now been expanded to include the S gene region of the virus. 

In addition, LGC Biosearch Technologies has launched new assays in its ValuPanel line. The Charité 2019-nCoV BHQ and BBQ-650 ValuPanel Reagent sets use oligonucleotide sequencedesigned by the German Center for Infection Research (DZIF) at Charité. The firm also now offers US CDC 2019-nCoV BHQ ValuPanel Reagents sets, and continues to offer the 2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2.

May 01, 2020

CloudLIMS LIMS for COVID-19 Testing

Laboratory informatics provider CloudLIMS has launched its rapid deployment LIMS preconfigured for COVID-19 testing. The LIMS can be set up for SARS-CoV-2 testing in two to four days and comes preloaded with tests approved by the US Food and Drug Administration and US Centers for Disease Control and Prevention, as well as report templates and workflows to maximize testing and reporting capability of labs doing COVID-19 testing. 

May 01, 2020

Microbiologics SARS-CoV-2 RNA Process Control

Microbiologics has launched two new research-use-only products for COVID-19 research and quality control: a protein-coated RNA process control and an IVD control with pooled gene targets.

The new SARS-CoV-2 control features diagnostically relevant RNA sequences protected by phage protein, providing nuclease resistance even in nuclease-rich environments such as nasal secretions or plasma. This coating protects the RNA during the extraction process, preventing the false negatives that can occur with the use of naked RNA. The protein coating functions like the virus's protective envelope that sequesters and protects its RNA genome. Featuring genomic targets for all seven WHO COVID-19 testing protocols, this process control can be used for SARS-CoV-2 assay development, positive extraction, and spike-in controls.

The new SARS-CoV-2 Helix Elite control features a pool of large RNA molecules that match the viral sequences for the RdRp gene, S gene, E gene, and N gene. These pooled genetic targets offer broad compatibility with CDC- and WHO-specified test components to generate positive PCR signals.

Apr 29, 2020

ProteoGenix Human Immune COVID-19 Library

ProteoGenix has launched a Human Immune COVID-19 Library to facilitate the discovery of antibodies against SARS-CoV-2. Created using blood samples from dozens of recovered COVID-19 patients, the library is adapted for screening with phage display and features 1.2 x 1010 different clones. The phage display screening technology coupled with the library's diversity is expected to speed the discovery of antibodies with the strongest affinity, specificity, and viral blocking activity, the company said. ProteoGenix said that it also offers a broad diversity of ready-made SARS-CoV-2 antigens, as well as custom antigen development services. Within eight weeks, clients can receive three to 10 unique and royalty-free antibody sequences with optimal affinity.

Apr 28, 2020

LabVantage COVID-19 Biobanking Accelerator

LabVantage Solutions has introduced COVID-19 Biobanking Accelerator to help laboratories rapidly implement COVID-19 biobanking, testing, and research programs. Based on the existing LabVantage laboratory information management system, the COVID-19 Biobanking Accelerator can accommodate tests including reverse transcription PCR, isothermal nucleic acid amplification, and serology, according to Centers for Disease Control and Prevention or customer-specified testing protocols. The company said that new users can be live on the software-as-a-service platform in fewer than four weeks.

Apr 27, 2020

Meridian Bioscience Inhibitor Tolerant 1-Step RT-qPCR Mix

Meridian Bioscience launched its Inhibitor Tolerant 1-step RT-qPCR Mix, an enzyme master mix that eliminates the need for an RNA extraction kit before running a sample through a molecular assay. Meridian developed the master mix formulation because it said RNA isolation and purification is time consuming and expensive. The company also noted that RNA extraction kits have been in short supply during the COVID-19 pandemic. 

When combined with SARS-CoV-2 primers and probes, the proprietary master mix can be used by laboratories to eliminate RNA purification, reducing processing times by as much as 30 minutes and lowering test costs.  

Apr 27, 2020

Proscia: Concentriq Dx

Proscia has launched its Concentriq Dx digital pathology software in the US. The software can be used for reviewing and reporting digital pathology slides from remote locations, such as home offices, using an internet browser. Concentriq Dx was CE marked in November 2019. According to Proscia, Concentriq Dx will support the need for remote pathology in US during the coronavirus pandemic. The US Food and Drug Administration recently issued new guidance allowing the greater availability of remote digital pathology services during the pandemic. 

 
Apr 22, 2020

Skyline Dx: Merlin Assay

Skyline Dx launched the Merlin Assay for melanoma as a laboratory-developed test available through its CLIA/CAP facility in San Diego. According to the Rotterdam, Netherlands-based company, a recently published study found the test could reduce up to 42 percent of surgical interventions in patients diagnosed with melanoma. The assay was developed as a result of the Falcon R&D Program, a partnership between clinicians and academia to develop tools for optimizing the clinical pathway of melanoma patients. 

Apr 22, 2020

Centogene CentoSwab

Centogene has launched CentoSwab, a sample collection kit that is validated for pharyngeal sampling for the detection of SARS-CoV-2, the virus that causes COVID-19. The kit consists of a swab and a collection tube and will be distributed globally.

Apr 22, 2020

Caris Life Sciences MI Exome

Caris Life Sciences has launched MI Exome, a whole-exome next-generation sequencing-based assay.

The test covers 22,000 genes and detects point mutations, indels, copy number alterations, and about 250,000 exonic, intronic, and intergenic SNPs. MI Exome also includes analysis of tumor mutational burden, microsatellite instability, loss of heterozygosity, and homologous recombination deficiency, and can be used to interrogate bacteria, viruses and fungi, including cancer-related pathogens, to support microbiome analysis. Average turnaround time is less than 14 days. When paired with the Caris Molecular Intelligence profiling services, the test can help detect and characterize cancer to guide individualized treatment decisions, the company said.

Apr 21, 2020

Biocept RUO Target Selector Kits

Biocept has announced the availability of new research-use-only kits allowing molecular laboratories to perform some of its Target Selector molecular assays in house on both formalin-fixed paraffin-embedded tissue and circulating tumor DNA samples. The first available kits, for EGFR mutations, are being made available now and additional assays targeting other oncogene mutations are planned for launch in the future, Biocept said.
 
The firm's Target Selector technology platform utilizes patented "Switch-Blocker" technology to enrich specimens for specific mutations of interest, resulting in high assay sensitivity and specificity. According to the company, this high performance allows detection of minute fractions of mutated DNA in a liquid biopy sample, and could also allow laboratories to eliminate macro-dissection of tumor blocks or provide results with small DNA inputs compared to most tissue-based assays. Target Selector assays can be used in combination with a variety of low-cost analytical platforms including qPCR, Sanger sequencing, microarrays, and mass-spectrometry, in addition to next generation sequencing, the firm said.